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Abstract
The coexistence of neuronal mitochondrial pathology and synaptic dysfunction is an early 
pathological feature of Alzheimer's disease (AD). Cyclophilin D (CypD), an integral part of 
mitochondrial permeability transition pore (mPTP), is involved in amyloid beta (Aβ)-instigated 
mitochondrial dysfunction. Blockade of CypD prevents Aβ-induced mitochondrial malfunction 
and the consequent cognitive impairments. Here, we showed the elimination of reactive oxygen 
species (ROS) by antioxidants probucol or superoxide dismutase (SOD)/catalase blocks Aβ-
mediated inactivation of protein kinase A (PKA)/cAMP regulatory-element-binding (CREB) 
signal transduction pathway and loss of synapse, suggesting the detrimental effects of oxidative 
stress on neuronal PKA/CREB activity. Notably, neurons lacking CypD significantly attenuate 
Aβ-induced ROS. Consequently, CypD-deficient neurons are resistant to Aβ-disrupted PKA/
CREB signaling by increased PKA activity, phosphorylation of PKA catalytic subunit (PKA C), 
and CREB. In parallel, lack of CypD protects neurons from Aβ-induced loss of synapses and 
synaptic dysfunction. Furthermore, compared to the mAPP mice, CypD-deficient mAPP mice 
reveal less inactivation of PKA–CREB activity and increased synaptic density, attenuate 
abnormalities in dendritic spine maturation, and improve spontaneous synaptic activity. These 
findings provide new insights into a mechanism in the crosstalk between the CypD-dependent 
mitochondrial oxidative stress and signaling cascade, leading to synaptic injury, functioning 
through the PKA/CREB signal transduction pathway.
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1. Introduction
Alzheimer's disease (AD) is a chronic neurodegenerative disease characterized by 
progressive learning and memory deficits [1,2]. Synaptic failure is an early 
neuropathological hallmark in AD patients and AD animal models. The cognitive decline in 
AD is closely correlated to pathological synaptic changes, suggesting that synaptic distress 
is an underlying factor in AD pathogenesis [3,4]. Occurring along with synaptic failure, 
brain mitochondrial dysfunction is also an early pathology in AD. Human AD and AD 
animal models demonstrate mitochondrial pathologies including respiration deficits, 
increased generation/accumulation of free radicals, impaired energy metabolism [5–13], 
change in mitochondrial dynamics [14–18], and compromised calcium buffer capacity 
[19,20]. Recent studies highlighted the significance of mitochondrial Aβ accumulation 
[5,7,8,11,19,21–23]. The coexistence of mitochondrial alterations with synaptic perturbation 
warrants investigation of a link between synaptic failure and mitochondrial pathology in 
AD.
Cyclophilin D, a key component of mitochondrial permeability transition pore (mPTP), 
plays an integral role in Aβ-induced mitochondrial and synaptic injury [19,24,25]. However, 
the effect of CypD on Aβ-mediated cell signaling cascades controlling synaptic plasticity 
and activity has not been elucidated.
The PKA/CREB signal pathway acts as a key regulator of synaptic plasticity and learning 
memory [26–31]. PKA/CREB signaling cascade is affected in Aβ-rich environment leading 
to dendritic spine architecture change in an AD mouse model [32], suggesting the 
deleterious role of PKA/CREB disturbances in synaptic alteration in AD. To date, there is 
no report on the effects of CypD-mediated perturbations on Aβ-induced disruption of PKA/
CREB pathway. Thus, it is essential to determine whether CypD-dependent regulation of 
mitochondrial signal transduction mechanisms via disrupted PKA/CREB signal pathway 
contributes to Aβ-induced synaptic injury.
The present study addresses the key questions noted here and elucidates new insights into 
mechanisms underlying CypD and Aβ-induced damage to synaptic structure and function, 
focusing on synaptic structure, oxidative stress, dendritic spine alternations, synaptic 
activity, and PKA/CREB-associated signal transduction and synaptic function.
2. Methods
2.1. Mice
Animal studies were approved by the Animal Care and Use Committee of University of 
Kansas in accordance with the National Institutes of Health guidelines for animal care. 
Transgenic mice expressing a mutant form of the human amyloid protein precursor (APP) 
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bearing both the Swedish (K670N/M671L) and the Indiana (V717F) mutations (J-20 line) 
[33], were crossed with Ppif−/− mice to generate CypD-deficient mAPP mice (mAPP/
Ppif−/−). Offspring of Tg mice were identified by PCR using primers for each specific 
transgene as previously described [19]. Twelve month old mice of either sex were used for 
the study.
2.1.1. Neuronal culture
Primary neuronal cultures were previously described [19]. Primary neurons were maintained 
in culture for 14 days before treatment. Neurons were incubated with probucol (10 μM) or 
superoxide dismutases (SOD, 200 U/ml)/Catalase (250 U/ml) for 30 min prior to the 
addition of Aβ (5 μM) for 2 h.
2.2. Measurement of PKA kinase activity
Mice cortical tissues or cultured neurons were lysed with extraction buffer (10 mM Tris–
HCl pH 7.4,100 mM sodium chloride, 1 mMEDTA, 1 mM EGTA, 1 mM sodium fluoride, 
20 mM sodium pyrophosphate, 2 mM sodium orthovanadate, 1% Triton X-100,10% 
glycerol, 0.1% SDS, 0.5% deoxycholate, 1 mM PMSF) containing protease inhibitor 
cocktail (Calbiochem, set V, EDTA free) and homogenized on ice. Proper amount of 
samples was added and the levels of intracellular PKA kinase activity were measured by 
PKA Kinase Activity Assay Kit (Assay Designs) according to manufacturer's instructions.
2.3. Preparation of oligomeric Aβ1–42
Oligomeric Aβ1-42 was prepared from synthetic Aβ1-42, as previously described [19,34]. 
Oligomeric composition of Aβ1-42 solution was characterized by mass spectrometry.
2.4. Immunoblotting analysis
Mice cortical tissues or cultured neurons were homogenized in extraction buffer (10 mM 
Tris–HCl pH 7.4, 100 mM sodium chloride, 1 mM EDTA, 1 mM EGTA, 1 mM sodium 
fluoride, 20 mM sodium pyrophosphate, 2 mM sodium orthovanadate, 1% Triton X-100, 
10% glycerol, 0.1% SDS, 0.5% deoxycholate, 1 mM PMSF) containing protease inhibitor 
cocktail (Calbiochem, set V, EDTA free). After centrifugation at 13,000 rpm at 4 °C, an 
equal amount of supernatant proteins was subjected to the immunoblotting with the 
following primary antibodies: mouse anti-phospho (ser133)-CREB IgG (Cell Signaling 
Technology), rabbit anti CREB IgG (Cell Signaling Technology), rabbit anti phospho 
(Thr197)-PKA C IgG (Cell Signaling Technology), mouse anti-PKA C IgG (BD 
Biosciences Pharmingen), rabbit anti-synaptophysin (Dako), mouse anti-α-Tubulin (Sigma). 
The immunoantigen was detected by goat anti-mouse or rabbit IgG conjugated with 
horseradish peroxidase (Sigma). We used NIH Image-J computer program for the 
quantification of the intensity of the immunoreactive bands.
2.4.1. Phosphorylated CREB and total CREB determination—The levels of 
phospho (Ser133)-CREB were measured after 10 min of exposure to 50 μM glutamate of 
neurons, which were pretreated with either 5 μM oligomeric Aβ1–42 alone or co-incubation 
of oligomeric Aβ1–42 with 3 μM rolipram or 5 μM forskolin. Rolipram or forskolin was 
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added 30 min before the addition of Aβ1–42. After 2 h Aβ1–42 preincubation, the culture 
medium was replaced by glutamate buffer (20 mM Hepes, 119 mM NaCl, 5 mM KCl, 2 mM 
CaCl2, 1 μM Glycine, 300 μM Glucose, 50 μM Glutamate). The osmolarity of glutamate 
buffer was adjusted to 325 mOsm by using sucrose, and pH was adjusted to 7.3 with 10 N 
NaOH. Cortical tissues or cultured neurons were homogenized in extraction buffer 
containing protease inhibitor cocktail. The levels of phospho-CREB and total-CREB in 
neuron were detected by immunoblotting and the levels in mice brain were determined by 
Enzyme-linked immunosorbent assay (ELISA) according to the manufacturer's instructions 
(Invitrogen).
2.5. MitoSox Red staining and flow cytometry assay
Neurons were exposed to 0.5 μM MitoSox Red (Invitrogen) for 30 min. After the staining, 
the culture medium was changed and neurons were kept in an incubator (5% CO2, 37 °C) 
for 20 min. Afterwards, neurons were trypsinized from the plates and subjected to flow 
cytometry (Becton Dickinson FACS Calibur) assay. The flow cytometric data were analyzed 
by Flowjo 7 (Tree Star). Unstained cells (no MitoSox red staining) were used as a control to 
detect the specific MitoSox signal. Gates to determine percent of MitoSox-positive cells 
were set to exclude unstained control cells [35].
2.6. Neuronal synaptic density
Synaptic density of cultured neurons was measured by counting synaptophysin clusters 
attaching to neuronal dendrites and presented as the number of synaptophysin clusters per 
micron of dendrite. Neurons were fixed in 4% paraformaldehyde for 20 min and then 
blocked in 10% goat serum for 30 min. Synaptophysin was visualized by rabbit anti-
synaptophysin IgG (Dako) followed by goat anti-rabbit IgG conjugated with TRICT (Sigma-
Aldrich Corp.). Neuronal dendrites were visualized by mouse anti-MAP2 IgG (Boehringer 
Mannheim) followed by goat anti-mouse IgG conjugated with FITC (Sigma-Aldrich Corp.). 
Images were taken under a Biorad confocal and analyzed by NIH Image J program.
2.7. Electrophysiology
Brain slices were prepared from 12-month-old mice. Mice brain was sliced in ice-cold 
oxygen modified artificial cerebrospinal fluid (ACSF, 125 mM NaCl, 2.5 mM KCl, 2 mM 
CaCl2, 1.5 mM MgCl2, 26 mM NaHCO3 and 10 mM glucose). Brain slices were then 
recovered in ACSF for 60 min at 32 °C. 1 μM tetrodotoxin was added to the bath while 
patch recording. Whole-cell recording was conducted on pyramidal neurons in hippocampal 
CA1 region. The patch pipettes were filled with intracellular solution containing 115 mM 
cesium methanesulfonate, 20 mM CsCl, 10 mM HEPES, 2.5 mM MgCl2, 10 mM sodium 
phosphocreatine, 4 mM Na2ATP, 0.4 mM Na3ATP and 0.6 mM EGTA, pH 7.3. The 
spontaneous miniature excitatory postsynaptic currents (mEPSCs) were recorded by using 
MultiClamp 700A (Axon Instrument) and the events were analyzed using Axon clampfit 
(Axon Instrument, version 8.2.0.235).
Du et al. Page 4






















2.8. Dendritic spine density and morphology measurements in vivo
CA1 neurons from mice brain slices were microinjected by using patch pipettes filled with 
intracellular solution as described above containing 0.1% Lucifer yellow CH (Sigma-
Aldrich Corp.). Spines on basal dendrites of CA1 neurons were visualized by rabbit anti-
Lucifer yellow Ig G (Sigma-Aldrich Corp.) followed by goat anti-rabbit IgG Alexa 488 
(Invitrogen). Images were taken under a Biorad confocal and Z stacks were gathered at 0.2 
μm increments. The types of spines were recognized based on the measurements. Spines 
were defined as stubby type if they had a length to neck diameter ratio less than 2. Spines 
with a length to neck diameter ratio more than 2 were categorized as mushroom type if the 
ratio of head to neck diameter more than 1.3 fold or thin spines if the ratio of head to neck 
diameter was less than 1.3 fold [36]. Data were analyzed by using Axiovision LE (Zeiss) 
software. Analysis of synaptic density and morphology was performed by an investigator 
blinded to mice genotypes.
2.9. Statistical analysis
We performed statistical analyses with Student's t-test and one-way analysis of variance 
(ANOVA) as well as post-hoc ANOVA (Tukey's) using the Statview statistics software 
when appropriate. P < 0.05 was considered significant. All data are expressed as means ± 
s.e.m.
3. Results
3.1. Aβ disturbs PKA/CREB signaling transduction pathway through oxidative stress
PKA activity significantly relies on PKA catalytic subunit (PKA C) phosphorylation on its 
Thr197 site, which is an integral part in PKA/CREB signal transduction pathway. Given that 
reactive oxygen species (ROS) is a determined factor for disturbing PKA C Thr197 
phosphorylation [37] and that Aβ is a known strong inducer of ROS production, we 
determine whether Aβ disturbs PKA/CREB signaling transduction through oxidative stress. 
To evaluate the effects of oxidative stress on Aβ-impaired PKA/CREB signaling cascades, 
we employed antioxidant probucol or SOD/catalase to extinguish extracellular as well as 
intracellular ROS as described in our previous studies [19,38,39]. Neurons were incubated 
with antioxidant probucol or SOD/catalase for 30 min prior to the addition of Aβ for 2 h. Aβ 
treatment significantly inhibited PKA C phosphorylation (Fig. 1A) and PKA activity (Fig. 
1B), while probucol or SOD/catalase treatment protected against Aβ-induced deleterious 
effects on PKA C phosphorylation and PKA activity (Fig.1A–B). Since CREB is a 
downstream target of PKA regulation, we extended our study by assessing CREB 
phosphorylation (pCREB) in response to glutamate stimulation. Glutamate is a strong 
mediator of CREB activation and previous study showed that glutamate-stimulated CREB 
phosphorylation is associated with PKA activity [40]. Our results showed that the 
application of probucol or SOD/catalase significantly reversed Aβ-reduced CREB 
phosphorylation (pCREB) (Fig. 1C1–C2). Probucol or SOD/catalase alone (without Aβ) had 
no effects on the baselines of p-PKA C levels, PKA activity or pCREB (Fig. 1A–C2). These 
data suggest that Aβ-associated oxidative stress is involved in PKA/CREB perturbations in 
Aβ-insulted neurons.
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3.2. CypD deficiency attenuates Aβ-induced mitochondrial ROS production and restores 
Aβ-perturbed PKA/CREB signaling transduction pathway in vitro
Previous studies have demonstrated that CypD-mediated mitochon-drial permeability 
transition pore (mPTP) is a critical mechanism underlying Aβ-induced mitochondrial and 
intracellular oxidative stress in Aβ-insulted neurons. We then performed studies to 
determine if CypD-mediated mitochondrial ROS is associated with Aβ-disrupted PKA 
activity. First, cultured nonTg and Ppif−/− neurons were exposed to Aβ and subjected to the 
detection of mitochondrial ROS production by employing MitoSox Red, a specific 
mitochondrial ROS indicator using flow cytometry. NonTg neurons showed substantially 
higher percentage of cells positive for MitoSox Red staining than Ppif−/− neurons (36.36 ± 
1.41% versus 22.75 ± 0.7% in gated area, Fig. 2A) at the exposure to Aβ. There's 
nosignificant difference in the percentage of MitoSox Red positive cells between nonTg and 
Ppif−/− vehicle-treatment groups. Furthermore, we employed cyclosporine A (CsA), a 
pharmacological inhibitor for blocking CypD activity. NonTg neurons were pre-exposed to 
5 μM CsA or vehicle (no CsA) for 1 h before the co-incubation with Aβ for 2 h, and then 
subjected to MitoSox Red staining. Aβ-treated nonTg neuronal mitochondria demonstrated 
significantly decreased MitoSox Red staining intensity in the presence of CsA, suggesting 
the application of CsA substantially suppressed Aβ-induced mitochondrial ROS elevation 
(Fig. 2B. Aβ-treatment vs. CsA and Aβ co-treatment, P = 0.019). The treatment of CsA 
alone was without significant effect on MitoSox Red intensity (Fig. 2B. CsA-treatment vs. 
control. P > 0.05). These data suggest that the blockage of CypD by genetic depletion or 
pharmacological inhibition suppresses Aβ-induced increase in mitochondrial ROS 
production/accumulation.
To determine the involvement of CypD in Aβ-instigated PKA/CREB signaling transduction 
change, we next evaluated alterations in PKA activity in Aβ-treated cultured neurons in the 
presence (nonTg) and absence (CypD-deficient, Ppif−/−) of CypD. Aβ treatment caused a 
time-dependent decrease in PKA activity in nonTg neurons compared to the vehicle 
treatment (Fig. 3A, Aβ 2 h: 0.76 ± 0.047, Aβ 6 h: 0.72 ± 0.032, Aβ 12 h: 0.61 ± 0.057, Aβ 24 
h: 0.59 ± 0.037 vs. vehicle:1 ± 0.056). In contrast, PKA activity in Ppif−/− neurons remained 
constant over the entire period of Aβ-treatment for 2 to 24 hours; and Aβ-insulted nonTg 
neurons demonstrated significantly suppressed PKA activity in comparison to their 
corresponding Aβ-treated Ppif−/− neurons. Utilization of KT5720, a selective inhibitor of 
PKA activity that acts as an antagonist at the PKA-ATP binding site of the PKA C, 
efficiently inhibited PKA activity in both types of neurons (Fig. 3A). These results indicate 
that lack of CypD rescues Aβ-induced inactivation of PKA.
Then, we examined the phosphorylation of the PKA C Thr197 (p-PKA C) in Aβ 
superimposed neurons. Aβ-treated nonTg neurons had a 45% decrease in p-PKAc compared 
to the vehicle control (Fig. 3B). No changes of p-PKA C were observed in Ppif−/− neurons 
(Fig. 3B). The close correlation of decrease in p-PKA C to reduced PKA activity indicates 
that Aβ-induced dephosphorylation of PKA C is responsible for inhibiting PKA activity, and 
that CypD deficiency attenuates Aβ-induced inhibitory effect on PKA activation.
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At last, we examined the effect of CypD deficiency on Aβ-induced CREB phosphorylation. 
In the presence of Aβ, glutamate-induced pCREB was significantly reduced in nonTg 
neurons as compared with the vehicle control (Fig. 3C); while the pCREB level was 
substantially preserved in Aβ-insulted CypD-deficient neurons (Fig. 3C). The addition of 
rolipram (3 μM) or forskolin (5 μM) that activates PKA reversed Aβ-induced depression of 
pCREB (Fig. 3C), indicating that the PKA activation is critical for enhancing CREB activity 
against Aβ toxicity. It is noted that the expression levels of total CREB remained no 
significant changes among indicated groups of cells. These studies indicate that CypD 
abrogation protects against Aβ-induced down-regulation of the PKA signaling cascade.
3.3. CypD deficiency rescues Aβ-induced loss of synapses associated with PKA/CREB 
signaling transduction pathway preservation
PKA/CREB signaling transduction pathway plays an essential role in controlling and 
regulating synaptic plasticity. To address whether CypD-deficiency protected PKA/CREB 
signal transduction pathway connects to synaptic damage in Aβ-insulted neurons, we 
analyzed the effect of CypD depletion on Aβ-induced synaptic loss. Synapses were 
identified as synaptophysin-positive clusters attaching to dendrites. The recruitment of the 
presynaptic protein, synaptophysin to form synaptophysin-positive clusters is synaptic 
activity dependent and in a rapid manner [41]. Synaptophysin expression level in Aβ treated 
nonTg and Ppif−/− neurons were detected by Western blot. The level of synaptophysin 
expression was significantly reduced by 50% in Aβ-treated nonTg neurons compared to the 
vehicle treated groups (Fig. 4A). CypD deficiency largely reversed Aβ-induced decrease in 
synaptophysin expression (14% decrease in Ppif−/− neurons compared to nonTg neurons in 
the presence of Aβ). Synaptic density was quantified as the number of synaptophysin 
positive clusters per micron of dendrite length. After Aβ treatment, synaptic density in 
nonTg neurons was decreased by 41% in comparison to those in vehicle-treated controls 
(Fig. 4B, Aβ: 0.415 ± 0.024 versus vehicle: 0.647 ± 0.021); while CypD deficiency largely 
reversed Aβ-induced decrease in synaptic density (Fig. 4B, Ppif−/−: 0.510 ± 0.018 versus 
nonTg: 0.415 ± 0.024). Forskolin, PKA activator, protected against Aβ-induced synaptic 
density loss (Fig. 4B, Forskolin: 0.656 ± 0.022 versus Aβ: 0.415 ± 0.024), indicating that 
Aβ-induced loss of synapses associated with PKA/CREB signaling transduction pathway. 
CypD-deficiency also largely reversed Aβ-induced decrease in postsynaptic GluR1 cluster 
(S1).
In furtherance, antioxidant probucol or pharmacological scavengers of ROS (SOD/catalase) 
were added to neurons in culture to determine the effect of oxidative stress. As shown in 
Fig. 4C, antioxidants remarkably reversed Aβ-induced synaptic loss. In the presence of Aβ, 
nonTg neurons demonstrated a decrease of 34.2% in synaptic density in comparison to the 
vehicle control (Fig. 4C), while SOD/catalase and probucol significantly increased synaptic 
density by 30–35% (Fig. 4C; SOD/catalase + Aβ: 0.538 ± 0.027, probucol + Aβ: 0.559 ± 
0.023). Neither SOD/catalase nor probucol alone interfered with synaptophysin cluster 
density in neurons (Fig. 4C). The results of in vitro synaptic density experiments suggest 
that either CypD depletion or elimination of ROS by antioxidants protects synapses against 
Aβ insults, which is in accordance with preserved PKA/CREB signaling transduction 
pathway in an environment enriched for Aβ.
Du et al. Page 7






















3.4. CypD deficiency suppresses oxidative stress in mAPP mice
As aforementioned, our results showed that Aβ-impaired PKA/CREB signaling transduction 
cascade is closely correlated with CypD-associated oxidative stress in vitro neuronal culture. 
Next, we extended our observation on the protective effect of CypD deficiency in an in vitro 
cultured neurons to an in vivo AD mouse model overexpressing Aβ (mAPP mice) that 
resembles Aβ pathology in human AD brain. Brain cortexes derived from 12-month old 
mAPP mice, age-matched nonTg, CypD deficient, and CypD-deficient mAPP mice were 
subjected to the assay of oxidative stress marker 4-HNE (4-Hydroxynonenal). mAPP mice 
demonstrated significantly higher levels of 4-HNE than nonTg littermates (Fig. 5A; P = 
0.0267). In contrast, the 4-HNE level was significantly reduced in CypD-deficient mAPP 
mice (Fig. 5A; mAPP mice vs. mAPP/Ppif−/− mice, P = 0.0321). CypD deficient mice did 
not show significant difference in 4-HNE level as compared to nonTg mice (Fig. 5A; P > 
0.05). These results are consistent with our previous study showing that CypD-deficient 
mAPP mice had less mitochondrial ROS level than mAPP mice at the age of 12 months 
[19]. In combination, our results suggest that CypD deficiency protects brains from 
oxidative stress in mAPP mice, which is correlated to our in vitro results on the protective 
effect of CypD depletion on Aβ-induced ROS production.
3.5. CypD deficiency protects PKA/CREB signaling transduction pathway in mAPP mice
In view of the protective effects of CypD deficiency on Aβ-impaired PKA/CREB signaling 
transduction pathway and the subsequent synaptic change in anin vitro neuronal culture 
model, we examined the involvement of CypD-related perturbation in PKA/CREB pathway 
in mAPP mice. We first measured PKA activity in brain extracts of Tg mice including 
nonTg, APP/Aβ overexpression (mAPP), CypD deficient (Ppif−/−) and CypD-deficient 
mAPP (mAPP/Ppif−/−) mice at 12-month-old. Consistent with the effect of Aβ on in vitro 
cultured neurons, PKA activity was significantly lowered in mAPP mice than in nonTg 
littermate controls, while PKA activity in mAPP/Ppif−/− mice was effectively restored (Fig. 
5B). Accordingly, p-PKA C levels were significantly suppressed in mAPP mice but not in 
mAPP/Ppif−/−, nonTg and Ppif−/− mice (Fig. 5C).
Next, we measured levels of phosphorylation of CREB ser133 (pCREB) in cortex extracts 
by ELISA. The levels of pCREB were significantly reduced in mAPP mice as compared 
with nonTg mice (30% decreased over nonTg mice), whereas mAPP/Ppif−/− mice had 
higher levels of pCREB than mAPP mice (Fig. 5D). The levels of pCREB in nonTg mice 
were comparable to Ppif−/− mice. Total CREB levels were not changed among all the groups 
of mice. These observations indicate that abrogation of CypD rescues PKA/CREB signaling 
trans-duction pathway in mAPP mice.
3.6. Lack of CypD improves synaptic activity/transmission and alleviates deficits in 
dendritic spine architecture in mAPP mice
To determine the involvement of CypD in synaptic activity, we analyzed changes in 
Spontaneous Miniature Excitatory Postsynaptic Currents (mEPSCs) in CA1 neurons in brain 
slices from 12-month-old mAPP mice compared to those from nonTg, Ppif−/− and mAPP/
Ppif−/− mice. The amplitude of mEPSCs in mAPP neurons was significantly decreased by 
24% as compared to those in nonTg neurons (Fig. 6A, mAPP: 10.08 ± 0.28 versus nonTg: 
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13.28 ± 0.79). Similarly, the mEPSC frequency in mAPP neurons was substantially reduced 
by 38.5% (Fig. 6B, mAPP: 0.24 ± 0.046 versus nonTg: 0.39 ± 0.44). Importantly, CypD 
deficiency significantly restored mEPSC amplitude and frequency in mAPP/Ppif−/− neurons 
(Fig. 6A–B, amplitude: 11.45 ± 0.47, frequency: 0.39 ± 0.044).
We next studied whether the impairments in synaptic activity were linked to the loss of 
dendritic spines and changes in spine morphology. Since the basal dendrites of CA1 neurons 
receive input from CA3 neurons through Schaffer collaterals and are thought to be an 
infrastructure basis of the consolidation of long term potentiation [42], we analyzed basal 
dendritic spine architecture in the hippocampal CA1 neurons of Tg mice. We measured 
spine density and found that mAPP CA1 neurons had 20% less spine density than nonTg 
CA1 neurons (Fig. 7A1, 0.83 ± 0.088 versus 1.03 ± 0.032 per micron), whereas mAPP/
Ppif−/− CA1 neurons showed a smaller decrease (∼4%) in dendritic spine density (Fig. 7A1, 
0.97 ± 0.035 versus 1.03 ± 0.032 per micron). Cumulative percentile curves of spine density 
displayed an apparent left shift in mAPP neurons compared to those of nonTg, Ppif−/− and 
mAPP/Ppif−/− neurons (Fig. 7A2). These results demonstrate the protective effect of CypD 
depletion on the dendritic spine loss in mAPP mice.
We then evaluated the effect of CypD on dendritic spine morphology by intra-neuronal 
injection of Lucifer yellow (Fig. 7E, S2-3) and categorized dendritic spins into three groups 
(mushroom, stubby and thin) [36,43]. Results of quantitative analysis of basal dendritic 
spines in nonTg CA1 neurons showed 43.2%, 12.3%, and 44.6% for mushroom, stubby, and 
thin spines, respectively. Interestingly, mAPP CA1 neurons showed a significantly 
decreased percentage of mushroom spines (Fig. 7B1–2, mAPP: 24.31 ± 1.02 versus nonTg: 
43.18 ± 1.72), but an increased percentage of stubby spines (Fig. 7C1–2, mAPP: 25.47 ± 
1.36 versus nonTg: 12.25 ± 0.83). Besides there was a 10% increase in thin spines in mAPP 
neurons (Fig. 7D1–2, mAPP: 50.22 ± 1.11 versus nonTg: 45.20 ± 1.70), suggesting that 
dendritic spine maturation is altered in mAPP mice. Remarkably, CypD-deficient mAPP 
neurons significantly preserved dendritic spine morphology as shown by an increased 
percentage of mushroom spines (Fig. 7B1, 35.26 ± 1.1) and reduced percentage of stubby 
spines (Fig. 7C1, 17.04 ± 1.19). Plots of cumulative percentage curves for the different types 
of dendritic spines clearly showed a substantial left shift of the curve for mushroom spines 
and a right shift for stubby spines in mAPP CA1 neurons, while the indicated curves of 
mushroom or stubby spines of mAPP/Ppif−/− neurons fell between those of mAPP and 
nonTg neurons (Fig. 7B2 and C2). Notably, CypD deficient neurons demonstrated increased 
percentage of thin spines comparing to nonTg neurons, while there is no significant 
difference in the percentage of mushroom and stubby spines between nonTg and CypD 
deficient neurons suggesting the dendritic spine development in Ppif−/− neurons is more 
active. Taken together, these data indicate that CypD depletion significantly preserves 
dendritic spine maturation and morphology with improved synaptic activity, and ultimately 
attenuated synaptic degeneration in mAPP mice.
4. Discussion
The synchronization of mitochondrial pathology and synaptic alterations in AD has been 
previously acknowledged, but the mechanism underlying the interplay of neuronal 
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mitochondrial dysfunction and synaptic change in AD remains largely unknown. This study 
was the first report that CypD mediates PKA signaling perturbation contributes to Aβ-
induced synaptic damages including alterations in synaptic structure and synaptic function. 
First, we showed that CypD-deficiency attenuated Aβ-mediated reduction in PKA activity 
and phosphorylation of PKA C and CREB. Second, antioxidant probucol or SOD/catalase, 
pharmacological scavengers of ROS blunted Aβ-induced inactivation of PKA/CREB 
signaling. Third, neurons lacking CypD were resistant to Aβ-induced loss of synapses. 
Finally, these protective effects of CypD deficiency on disruption of signal transduction and 
deficits in synaptic structure and function were observed in CypD-deficient mAPP mice in 
contrast with mAPP mice. Our results indicate that CypD-mediated increase in 
mitochondrial and intracellular oxidative stress inhibits PKA catalytic subunit 
phosphorylation and subsequently disrupts the PKA/CREB signaling transduction pathway, 
eventually leading to structural and functional synaptic deterioration. Notably, abrogation of 
CypD restores PKA/CREB signaling and attenuates further synaptic aberrations. In 
conclusion, CypD-mediated PKA/CREB signal transduction disruption appears to be an 
important player in the scenario leading to synaptic injury in Aβ milieu (Fig. 8).
Oxidative stress is culprit for many intracellular perturbations like protein misfolding and 
inactivation, nucleic and mitochondrial DNA injuries [44–46]. Increasing evidence has 
shown that oxidative stress alters PKA activity and phosphorylation of CREB, which is 
detrimental to cell survival [47,48]. Indeed, we demonstrated that the phosphorylation of 
PKA C subunit at Thr197 is susceptible to the insult of pro-oxidant (t-butyl hydroperoxide, 
TBH) (S4). Aβ is a strong instigator of both extracellular and intracellular ROS production 
leading to intra-cellular oxidative stress and protein oxidation in AD brains. In this study, we 
employed SOD/catalase to scavenge extracellular and intra-cellular oxidative stress aroused 
by Aβ, respectively. Given that probucol is an antioxidant preventing protein or lipid 
peroxidation and that the addition of probucol attenuates oxidative stress [38,39], we also 
chose probucol as an antioxidant for this study. Consistent with the results from SOD/
catalase, ROS scavengers, probucol treatment significantly blocked inhibitory effects of Aβ 
on phosphorylation of PKA C, PKA activity, pCREB (Fig. 1), and density of synapses (Fig. 
4).
The application of antioxidants significantly protects neurons from Aβ-induced inactivation 
of PKA, suggesting that Aβ-associated oxidative stress underlies perturbed PKA/CREB 
signaling transduction in AD. In fact, the treatment of Aβ also has effect on inducing mito-
chondrial ROS overproduction. We propose that Aβ induces the formation of mPTP, which 
is a severe mitochondrial pathology in AD, resulting in mitochondrial ROS overproduction 
and release to cytosol to break cytosolic Redox balance [19]. In correlation with previous 
reports that the depletion of CypD significantly diminishes mitochondrial ROS generation 
and suppresses the subsequent cytosolic ROS elevation, our results demonstrate that CypD 
deficiency is closely associated with preserved PKA activity and the downstream CREB 
signaling cascade from Aβ toxicity. Aβ-induced mitochondrial ROS perturbation through 
CypD-mediated mPTP contributes to PKA/CREB disturbances in AD. It is noted that 
increased intracellular ROS is an inductive factor of CypD-mediated mPTP formation, 
which in turn results in mitochondrial ROS overproduction and release, and eventually 
exaggerated intracellular oxidative stress. The feed-back loop of intracellular oxidative 
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stress and mPTP-associated ROS has been well documented. Several previous studies have 
demonstrated that the application of antioxidants including exogenous SOD/catalase to 
prevent oxidizing reagent-induced extra- and intra-cellular oxidative stress is effective in 
blunting mPTP formation and thusly reducing ROS-associated oxidative stress in cells 
[49,50]. It therefore serves as indicative evidence that the antioxidants we adopted in this 
study attenuated Aβ-suppressed PKA/CREB activity at least partially through the inhibition 
of CypD-mediated mPTP formation. Indeed, CypD-associated cytosolic ROS elevation is 
closely related to the formation of mPTP, which is a mechanism of mitochondria-generated 
ROS release. The application of mitochondria-targeted antioxidants might be another option 
to extinguish the mPTP-associated mitochondrial ROS production and further protect PKA 
signaling cascades from Aβ toxicity. In fact, several studies have suggested that the 
application of mitochondria-targeted antioxidants significantly attenuated CypD-associated 
cell perturbations [51,52]. However, recent studies showed that the application of 
mitochondria-targeted antioxidants such as MitoQ and Resveratrol substantially decreased 
the expression level of CypD in primary cultured hippocampal neurons, suggesting the 
modulating effect of mitochondria-targeted antioxidants on CypD transcription and 
expression [51]. In view of the purpose of the current study to reveal the mechanisms 
underlying CypD-mediated mPTP and cytosolic PKA activity disturbances, we chose 
antioxidants only targeted to intracellular and extracellular ROS without interfering the 
baseline expression levels of CypD under our experimental conditions (data not shown). The 
dual effects of mitochondria-targeted antioxidants that diminish mitochondrial ROS and 
down-regulate CypD expression levels suggest that mitochondria-targeted antioxidant is a 
promising strategy against CypD-associated neuronal stresses. We will perform a detailed 
study to evaluate the effect of mitochondria-targeted antioxidants as a treatment strategy for 
AD in our future work.
Intracellular oxidative stress and calcium elevation are two major consequences of CypD-
mediated mPTP formation. We have shown that increased intracellular ROS significantly 
inhibits PKA activity. We then tested the effects of elevated intracellular calcium on PKA 
by using A23187 (calcium ionophore). Administration of A23187 to nonTg neurons did not 
change PKA C phosphorylation (data not shown), suggesting PKA C phosphorylation is not 
sensitive to intracellular calcium elevation. In view of our data showing the protective 
effects of antioxidants (SOD/catalase, and probucol) and CypD blockade on Aβ-impaired 
PKA/CREB signal, CypD-associated oxidative stress is likely to be a major player for Aβ-
induced suppression of PKA activity.
The PKA/CREB signaling cascade plays a crucial role in regulation of neuronal/synaptic 
function, such as synaptic maturation and long-term memory consolidation. PKA untethers 
synaptic vesicles, regulates the functions of NMDA (N-methyl-D-aspirate receptor) and 
AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazole propionate receptor) receptors and 
phosphorylates several synapse-related proteins (i.e., PSD95, snapin and synapsin), 
suggesting that PKA is critical for synaptic transmission, dendritic spine architecture and 
synaptic maturation [26,31,53–55]. Notably, PKA function depends on the activation of 
PKA C and activation of PKA C relies on phosphorylation at the proper sites, Thr197. 
Phosphorylation at Thr197 site stabilizes PKA C structure, exposes its activation site, and 
facilitates its binding to PKA regulatory subunit [56,57]. Our study provides evidence of the 
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negative effect of CypD-associated oxidative stress on PKA C Thr197 phos-phorylation, 
PKA activity and CREB phosphorylation, leading to a compromised PKA/CREB signaling 
cascade; and as a contrast, genetic depletion of CypD significantly blocked Aβ-induced 
PKA deactivation. Furthermore, application of CypD inhibitor has a protection against Aβ-
induced PKA perturbations. It is possible that CypD/Aβ-dependent synaptic dysfunction 
may also involve other mechanisms such as decreased synaptic mitochondrial energy 
production and disturbed Ca2+-regulated signaling pathways including calmodulin-
dependent protein kinase II (CaMKII), calcineurin and/or Protein Kinase C (PKC) in 
addition to PKA/CREB pathway [34,40,58–60]. These CypD-related changes are potential 
mechanisms in addition to deactivation of PKA/CREB pathway, contributing to synaptic 
degeneration in AD; hereby, further investigations are also required for elucidating these 
alternative mechanisms.
In view of the involvement of CypD in Aβ-mediated oxidative stress and PKA/CREB 
signaling transduction pathway perturbation, we propose that sustained CypD-induced 
neuronal/synaptic mitochondrial stress is a potential mechanism responsible for synaptic 
failure in the pathogenesis of AD. Our postulation is based on our finding that mAPP mice 
revealed abnormalities in dendritic spine architecture, dendritic spine maturation, and 
spontaneous synaptic activity. These synaptic alterations were substantially reversed in 
CypD-depleted mAPP mice. Together with the protection of CypD ablation on Aβ-induced 
impairments in hippocampal long-term potentiation (LTP) and learning/memory ability 
[19,25], our studies gain new insights into the role of CypD-dependent mitochondrial ROS 
in disturbing synaptic plasticity and maturation in AD. Hence, blockade of CypD may be 
potential therapeutic strategy for preventing and halting synaptic and mitochondrial 
pathology in Alzheimer disease.
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Antioxidants attenuated Aβ-induced inhibitory effects on pPKA C and pCREB levels. (A) 
The treatment of SOD (200 U/ml)/catalase (250 U/ml) or probucol (10 μM) significantly 
attenuated Aβ (5 μM, 2 h)-induced decrease in pPKA C level. Densitometry of the pPKA C 
immunoreactive bands relative to the total PKA C was shown in the indicated groups of 
cells. The lower panel showed representative immunoblots for pPKA C and total PKA C in 
the indicated groups. (B) The treatment of antioxidants attenuated Aβ-induced reduction in 
PKA activity. (C1–C2) Densitometry of the immunoreactive bands for phospho-CREB 
(pCREB) relative to the total CREB in the indicated groups of cells. Levels of pCREB were 
increased in cells treated with SOD/catalase (C1) and probucol (C2) in the presence of Aβ. 
The lower panels in C1 and C2 showed the representative immunoblots for pCREB and total 
of CREB. Results were derived from 3 to 5 independent experiments.
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Effects of CypD-deficiency on mitochondrial ROS production in neurons exposed to Aβ. 
(A) Aβ-treated neurons were subjected to MitoSox Red staining and the percentage of 
MitoSox Red-positive cells was quantified by flow cytometry. (B) CsA treatment 
significantly attenuated MitoSox Red intensity in Aβ-exposed neurons. Scale bar = 10 μm.
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Effects of CypD-deficiency on PKA activity, phosphorylation of PKA C (p-PKA C), and 
pCREB in neurons exposed to Aβ. (A) PKA activity in cultured nonTg and Ppif−/− neurons 
exposed to oligomeric Aβ for 2, 6, 12 and 24 h, respectively. KT5720 (1 μM), a PKA 
inhibitor, was added to neurons. PKA activity in the indicated cell lysates was determined 
by PKA Kinase Activity Assay Kit. The data were expressed as fold increased relative to the 
PKA activity in vehicle-treated nonTg neurons. (B) NonTg and Ppif−/− neurons were treated 
with 5 μM Aβ for 2 h, then subjected to immunoblotting for phosphorylation of PKA C 
Thr197, and total PKA C. Quantification of intensity of phospho-PKA C immunoreactive 
bands normalized to total PKA C is presented in the upper panel. The lower panels represent 
the sample immunoblots for phospho-PKA C Thr197 and PKA C subunit. (C) Effect of 
CypD deficiency on glutamate-induced phosphorylation of CREB. Cortical neurons were 
exposed to 5 μM Aβ for 2 h in the presence or absence of glutamate stimulation, and then 
subjected for immunoblotting for pCREB Ser133 and total CREB. Densitometry of pCREB 
immunoreactive bands normalized to total CREB is presented in the upper panel and the 
lower panel shows representative immunoblots for pCREB and CREB. Rolipram (3 μM) and 
Forskolin (5 μM) were added to cultured neurons.
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Effects of CypD deficiency and antioxidant on Aβ-induced synaptic loss. (A) Expression 
levels of synaptophysin in Aβ-treated nonTg and Ppif−/− neurons. Cultured neurons were 
treated with 5 μM oligomer Aβ1–42 for 2 h. Cell lysates were subjected to immunoblotting 
with synaptophysin antibody. Densitometry of the synaptophysin immunoreactive bands 
was normalized by α-tubulin using NIH Image J software. The lower panels are 
representative immunoblots for synaptophysin and α-tubulin. Data were collected from 3 to 
4 independent experiments. (B) After exposure of 5 μM oligomer Aβ for 2 h, Ppif−/− 
neurons exhibited preserved synaptic positive clusters compared with nonTg neurons. PKA 
activator, forskolin (5 μM), protected nonTg neurons against Aβ-induced synaptic loss. Data 
were collected from 17 to 20 neurons per group. The lower panel shows representative 
images of synaptophysin clusters (synaptophysin, red) and dendrite (MAP2, green) staining. 
Scale bar = 10 μm. (C) Antioxidants attenuated Aβ-induced synaptic loss. Data are derived 
from 16 to 23 neurons per group in 3 independent experiments. The right panel shows 
representative images of synaptic staining. Synapses were visualized by synaptophysin 
staining (red) and dendrites were shown by MAP2 staining (green). Scale bar = 10 μm.
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Effect of CypD deletion on brain oxidative stress, PKA activity, phosphorylation of PKA C 
and CREB in mAPP mice. (A) Cerebral cortexes from the indicated Tg mice were subjected 
to 4-HNE assay. CypD-deficient mAPP mice demonstrated significantly lowered 4-HNE 
level than mAPP mice. (B) PKA activity in the cerebral cortex of the indicated Tg mice. 
Data are shown in fold-increase relative to the PKA activity in nonTg mice. (C) 
Densitometry of immunoreactive bands for p-PKA C, total PKA C, and α-tubulin in the 
cerebral cortex homogenates of the indicated Tg mice. Data were expressed as fold-increase 
relative to pPKA C level (normalized to total PKA C) in nonTg mice. The representative 
immunoblots were demonstrated in lower panel. (D) CREB phosphorylation in Tg mice. 
Data were shown as fold-increase relative to total CREB.
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Effect of CypD on spontaneous synaptic activity in mAPP mice. mAPP mice showed 
decreased mEPSC amplitude (A) and frequency (B), which were restored by CypD 
deficiency. (C) The representative traces of mEPSC recorded for CA1 neurons from the 
indicated Tg mice. Scale = 20 pA, 500 ms.
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Effect of CypD deletion on dendritic spine architecture in mAPP mice. (A–D) 
Quantification of spine density (A) and types of synaptic morphology (B–D). (A) The 
comparison of spine density. N = 4–6 mice per group, 10, 11, 15 and 12 neurons from 
nonTg, Ppif−/−, mAPP mice, and mAPP/Ppif−/− mice, respectively. (B–D) The comparison 
of the percentage of mushroom (B1–2), stubby (C1–2), and thin (D1–2) type spines 
occupied by the total dendritic spines. (E) Representative images of basal dendritic spines of 
CA1 neurons in Tg mice. Dendritic spines (green) and senile plaques (red) were visualized 
by Lucifer yellow injection and 3D6 immunostaining, respectively. The panels i, ii, iii and iv 
show representative images of dendritic spines from nonTg, Ppif−/−, mAPP and mAPP/
Ppif−/− mice, respectively. The lower panels present outlines of the dendritic spines 
corresponding to the images above. Scale bar = 5 μm.
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Schematic figure of CypD deficiency protects synaptic plasticity and maturation against Aβ 
toxicity. In the presence of CypD, Aβ augments mitochondrial ROS production/
accumulation, subsequently decreases phosphorylation of PKA catalytic subunit and the 
resultant depression in PKA/CREB signaling transduction, eventually leading to synaptic 
degeneration. In contrast, the deficiency of CypD attenuates Aβ-instigated mitochondrial 
ROS production and thereby ameliorates PKA/CREB perturbation and improves synaptic 
plasticity and maturation in Aβ rich scenario.
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